Last updated: 2026-09-21 03:53:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Incannex Healthcare Limited (IXHL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.66, with a market capitalization of $43.55M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.49 to $20.31. This page covers its latest market performance, valuation, price trends and company information.
$43.55M | |
$3.58 | |
$2,700.00 | |
$2.40 | |
$3.59 | |
87.82K | |
145.93K | |
-- | |
$20.31 | |
$2.49 | |
-- | |
-- |
Incannex Healthcare Limited (IXHL) last closed at $3.59 as of 2026-09-18 23:51:00, unchanged from the previous close of $3.59.
During the latest regular trading session, IXHL traded between $2.40 and $2,700.00, with a volume of 87.82K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Incannex Healthcare Limited (IXHL) moved from $3.25 to $3.66, representing a gain of 12.74% ($0.41).
The stock traded between $3.17 and $3.84 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 140.34 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 6.6%
IXHL is currently trading at $3.66, placing it 6.6% of the way from its 52-week low of $2.49 to its 52-week high of $20.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Incannex Healthcare Limited (IXHL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.